AEON Biopharma, Inc. (AEON)
ASE · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
AEON Biopharma, Inc. — 8-K Filing
# 🧾 What This Document Is This is a press release filed with the SEC as an exhibit to a Form 8-K. Its purpose is to officially inform investors that AEON Biopharma has received a second notice from the NYSE American exchange about falling short of its financial listing standards. It clarifies that
March 2026
AEON Biopharma, Inc. — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which is like a major news bulletin a public company must send to the SEC. It announces important events. This specific filing contains a press release with two main stories: **AEON Biopharma's 2025 financial results** and **significant progress
SEC filings
All filings →Insider trades
All insider trades →AEON Biopharma, Inc. has no reported insider trades in the last 90 days.